Star Lake Technology: Introducing Strategic Investment Seamount in Future Space

Xinghu Technology Company's business can be divided into biochemical drugs, food additives and feed additives three parts: biochemical drugs including ribavirin, proline, adenine, creatine, birdside and proline, the profit is relatively stable;V7c
The continued growth in demand for susine, the impact of overseas production capacity, and the consolidation of Meihua Yipin, the improvement of the business climate is expected to lead to performance growth: the annual demand growth rate of susine is around 15-20%, the impact of avian influenza in 2013 has declined, after 2014 demand with the downstream aquaculture industry and a significant recoveryThe company's 35,000 tons of susine is in full production, is expected to bring a larger profit upward elasticityGlobal susine production capacity of 50-600,000 tons, plum production capacity will reach 200,000 tons, the concentration of increasedAccording to the estimates of supply and demand, the next 1-2 years of industry starts will continue to exceed 80%, the worst time has passed, the overall profit has improved significantlyV7c
Lysine profit slack, the formation of a bipolar pattern is expected to co-ordinate to enhance the industry climateMid-2011 to date lysine prices are basically in a unilateral downward trend, after many years of decapacity cycle prices have reboundedPlum combined Yipin after production capacity will reach 570,000 tons (15%), the domestic another leader Dentons biochemical capital pressure is greater, the formation of a double oligarch structure, we believe that the industry in the coming year is expected to come out of the low business climateThe company's 30,000 tons of lysine is in a state of discontinued production, but equipment maintenance is good, this part of the business in the future performance elasticity is also greaterV7c
The introduction of strategic investors, the company's business improvement can be expected, the future or biochemical drugs and health food field there is a larger imagination spacePrior to the company's non-public offering plan has been approved by the CSRC Development and Audit Committee, the issue of 95 million shares, the price of 3.85 yuan, Huili assets fully subscribed, after completion of the holding of 14.72 percent of the company's shares (the majority shareholder Guangxin Group holding 14.94 percent), the future or biochemical drugs and health food field there is a larger space for imagination V7c
　　The company's 2014-2016 EPS is expected to be -0.37, 0.36 and 0.44 yuan, and its performance is facing an inflection point The expectation sourcing of strategic investors and business transformation will bring about fundamental changes in the company, with long-term earnings improvements expected, raising the possibility of a valuation improvement and giving the company a "buy-A" rating V7c Star Lake Technology Company business can be divided into biochemical drugs, food additives and feed additives three parts: biochemical drugs including ribavirin, proline, adenine, creatine, birdside and proline, the profit is relatively stable; V7c
　　The continued growth in demand for susine, the impact of overseas production capacity, and the consolidation of Meihua Yipin, the improvement of the business climate is expected to lead to performance growth: the annual demand growth rate of susine is around 15-20%, the impact of avian influenza in 2013 has declined, after 2014 demand with the downstream aquaculture industry and a significant recovery The company's 35,000 tons of susine is in full production, is expected to bring a larger profit upward elasticity Global susine production capacity of 50-600,000 tons, plum production capacity will reach 200,000 tons, the concentration of increased According to the estimates of supply and demand, the next 1-2 years of industry starts will continue to exceed 80%, the worst time has passed, the overall profit has improved significantly V7c
　　Lysine profit slack, the formation of a bipolar pattern is expected to co-ordinate to enhance the industry climate Mid-2011 to date lysine prices are basically in a unilateral downward trend, after many years of decapacity cycle prices have rebounded Plum combined Yipin after production capacity will reach 570,000 tons (15%), the domestic another leader Dentons biochemical capital pressure is greater, the formation of a double oligarch structure, we believe that the industry in the coming year is expected to come out of the low business climate The company's 30,000 tons of lysine is in a state of discontinued production, but equipment maintenance is good, this part of the business in the future performance elasticity is also greater V7c
　　The introduction of strategic investors, the company's business improvement can be expected, the future or biochemical drugs and health food field there is a larger imagination space Prior to the company's non-public offering plan has been approved by the CSRC Development and Audit Committee, the issue of 95 million shares, the price of 3.85 yuan, Huili assets fully subscribed, after completion of the holding of 14.72 percent of the company's shares (the majority shareholder Guangxin Group holding 14.94 percent), the future or biochemical drugs and health food field there is a larger space for imagination V7c
　　The company's 2014-2016 EPS is expected to be -0.37, 0.36 and 0.44 yuan, and its performance is facing an inflection point The expectation sourcing of strategic investors and business transformation will bring about fundamental changes in the company, with long-term earnings improvements expected, raising the possibility of a valuation improvement and giving the company a "buy-A" rating V7c
Share it on feed